New Study Shows AML Ages Immune Cells, Leading to Poor Treatment Response
Nov 28, 2022
A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.
Relapsed Leukemia and Lymphoma Program News
Our team includes international leaders in leukemia and lymphoma treatment. Because we have treated so many children — including children who have come to us from around the world — we have a deep familiarity with this type of cancer.
Existing patients or family members
New patients, referrals and second opinions
CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing
May 23, 2022
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
CHOP Brings Together Experts to Discuss Precision Medicine in Pediatric Cancer Care
Mar 18, 2022
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
CHOP-Led Study Finds Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma
Mar 10, 2022
In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).
CHOP Researchers Develop Humanized CAR T-Cell Therapy that Shows Potential for Patients with Relapsed B-ALL
Jun 28, 2021
The treatment modifies a domain in the CAR that targets CD19, making it look more human and therefore less likely to be rejected by patients.
AML Immunotherapy Trial Opens
Jan 23, 2020
CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.
Humanized CD19: CAR-T Immunotherapy for First Relapse of ALL in Down Syndrome Patient
Jan 11, 2019
An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.
CHOP Scientists Report How Some Cancer Cells Develop Resistance to CAR T-cell Therapy
Nov 27, 2018
CHOP researchers analyze how some cancer cells resist a groundbreaking cellular therapy, and have found clues to overcoming that resistance.
Immunotherapy: What’s Next for CAR-T Therapy
Jan 24, 2019
Trials of more game-changing cell therapies for pediatric cancer and other diseases are underway or on the horizon at Children's Hospital of Philadelphia.
Parents Magazine Names Children’s Hospital of Philadelphia Among 20 Most Innovative Children’s Hospitals
Sep 5, 2018
Children’s Hospital of Philadelphia was recognized specifically for significant contributions to the development of a new treatment for a certain pediatric leukemia.